Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 5/20 | 0.36 |
| ▸ | FDFT1 | P37268 | 3/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | NPY1R | P25929 | 1/20 | 0.35 |
| ▸ | NPY4R | P50391 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13416894 | 0.95 | MTNR1A (0.39) | MTNR1AMTNR1BACHEFDFT1FAAH | |
| SCHEMBL13120730 | 0.90 | NPY4R (0.37) | MTNR1AMTNR1BACHEFAAHNPY1R | |
| SCHEMBL13416870 | 0.88 | NPY4R (0.38) | NPY1RNPY4R | |
| SCHEMBL13396434 | 0.85 | MTNR1A (0.36) | MTNR1AMTNR1BACHEFDFT1FAAH | |
| SCHEMBL13416281 | 0.83 | ACHE (0.44) | ACHE | |
| SCHEMBL13416875 | 0.83 | NPY4R (0.38) | NPY1RNPY4R | |
| SCHEMBL13396392 | 0.82 | MTNR1A (0.38) | MTNR1AMTNR1BFDFT1FAAH | |
| SCHEMBL13417055 | 0.80 | ACHE (0.40) | ACHE | |
| SCHEMBL13120725 | 0.80 | MTNR1A (0.35) | MTNR1AMTNR1BACHEFAAH | |
| SCHEMBL13416257 | 0.80 | ACHE (0.43) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2010-04-22 | — | — | US | disclosed |
| WO-2008095841-A2 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS2, NOS1 | MTNR1A 161/4885MTNR1B 76/4885ACHE 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.